TRILOGY AB ACETABULAR SYSTEM

FDA Premarket Approval P040048

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the trilogy ab acetabular system. The device is indicated for either cemented or noncemented use in skeletally mature individuals undergoing primary surgery for rehabilitating hips damaged as a result of noninflammatory degenerative joint disease (nidjd) such as osteoarthritis, avascular necrosis, congenital hip dysplasia, and traumatic arthritis.

DeviceTRILOGY AB ACETABULAR SYSTEM
Generic NameProsthesis, Hip, Semi-constrained, Metal/ceramic/ceramic/metal, Cemented Or Uncemented
ApplicantZIMMER, INC.
Date Received2004-12-14
Decision Date2006-06-28
Notice Date2007-06-28
PMAP040048
SupplementS
Product CodeMRA 
Docket Number07M-0259
Advisory CommitteeOrthopedic
Expedited ReviewNo
Combination Product No
Applicant Address ZIMMER, INC. p.o. Box 708 warsaw, IN 46581-0708
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Post-Approval Study:Show Report Schedule and Study Progress
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P040048Original Filing
S017 2012-04-06 135 Review Track For 30-day Notice
S016 2012-01-12 30-day Notice
S015 2011-06-14 Normal 180 Day Track No User Fee
S014 2011-05-02 Special (immediate Track)
S013
S012 2009-11-24 30-day Notice
S011 2009-11-23 30-day Notice
S010 2009-11-09 30-day Notice
S009 2009-09-14 Normal 180 Day Track No User Fee
S008 2009-05-11 Normal 180 Day Track No User Fee
S007
S006
S005 2008-04-17 30-day Notice
S004 2008-04-16 135 Review Track For 30-day Notice
S003 2007-11-30 135 Review Track For 30-day Notice
S002 2007-01-26 135 Review Track For 30-day Notice
S001 2006-10-12 Normal 180 Day Track No User Fee

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.